Q-omics provides the consensus-scored ZNF17 profile across patient tissues and cancer cell-line models. ZNF17 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF17 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZNF17 RNA expression shows 21,816 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZNF17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF17 survival associations across molecular data types. ZNF17 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF17 RNA expression–survival associations across cancer types. High ZNF17 expression shows unfavorable associations in MESO, LGG and ACC, but favorable associations in KIRC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF17 RNA expression.
This table summarizes ZNF17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF17 shows lower tumor expression in THCA, UCEC and KICH and higher tumor expression in LIHC, CHOL and HNSC. The THCA box plot shows higher ZNF17 RNA expression in normal versus tumor tissue (log2 FC = −1.038, t-test p < 0.001).
This table shows molecular features associated with ZNF17 in patient tissues and cancer cell lines. In patient samples, ZNF17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
